Entinostat and oral paclitaxel for advanced breast cancer
Treatments studied
Part of Cancer, Skin clinical trials.
This trial tests a combination of two drugs, entinostat and a pill form of paclitaxel, for people with a type of advanced breast cancer that is hormone receptor-positive and HER2-negative. It may be an option if you have already tried several treatments, including hormone therapy with a CDK4/6 inhibitor and a chemotherapy with paclitaxel.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have advanced breast cancer that is hormone receptor-positive and HER2-negative.
- You have at least one tumor that can be measured on scans.
- You have had 2 to 4 previous treatments, which must include a hormone therapy with a CDK4/6 inhibitor and a chemotherapy with paclitaxel.
- Your general health is good enough to perform daily activities (ECOG score 0-2).
- Your life expectancy is more than 6 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests adding entinostat (a drug that may help hormone therapy work better) to anlotinib or fulvestrant for people with HR-positive, HER2-negative advanced breast cancer that has worsened after prior hormone therapy and a CDK4/6 inhibitor. It aims to find a new treatment option for those who cannot use chemotherapy yet.
This trial tests a new combination of two targeted drugs (entinostat and pyrotinib) with hormone therapy for people with advanced, triple-positive breast cancer whose disease has progressed after trastuzumab (Herceptin). The goal is to see if this approach works better than current options.
This study tests a combination of two medicines (albumin-bound paclitaxel and a granulocyte-based therapy) for women with breast cancer that has come back or spread. It may be an option if you have already tried standard treatment and are looking for another approach.
This trial tests a combination of low-dose oral paclitaxel (a chemotherapy pill taken regularly) plus immunotherapy to treat advanced breast cancer that doesn't have high levels of HER2 protein. The goal is to slow or shrink tumors while managing side effects better than traditional high-dose chemotherapy.
This trial tests a combination of two drugs—entinostat and fulvestrant—for women with a certain type of advanced breast cancer (HR-positive, HER2-negative) that has stopped responding to standard hormone therapy and a CDK4/6 inhibitor. The goal is to see if this combo can help shrink tumors or slow their growth.
This trial tests an oral form of paclitaxel for people with advanced solid tumors, including breast cancer. It aims to see if swallowing the drug is safe and effective when standard treatments no longer work.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.